Agomab is focused on achieving disease modification by modulating fibrosis and regeneration in chronic indications such as fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. Its lead clinical candidate is AGMB-129, a gut-restricted oral small-molecule inhibitor of ALK5 (TGFβ1R) being evaluated in the Phase 2a STENOVA trial for fibrostenosing Crohn’s disease, with interim data expected in the first quarter of 2025. AGMB-447 is a lung-restricted inhaled small-molecule ALK5 inhibitor currently in a Phase 1 trial in healthy subjects and patients with idiopathic pulmonary fibrosis. AGMB-101 is a full MET agonistic antibody in the final stages of IND-enabling studies intended for development in liver cirrhosis. The company applies organ-restricted small molecules and high-affinity antibodies and highlights end-to-end R&D capabilities and a proven business-development track record. Proceeds from the recent financing will be used to advance clinical development across these programs. Agomab is a biology company focused on developing novel treatments to resolve fibrosis, repair tissue structure, and restore organ function. It combines new scientific insights with drug development to build a clinical pipeline of disease‑modifying programs in fibrotic diseases. Its lead candidate, AGMB-129, is a gut‑restricted small molecule ALK5 inhibitor that has started a Phase 2a STENOVA trial in Fibrostenosing Crohn’s Disease and received U.S. FDA Fast Track designation. A second TGFß‑targeting candidate, AGMB-447, is a Phase‑1‑ready lung‑restricted ALK5 inhibitor for idiopathic pulmonary fibrosis. AGMB-101 is an HGF‑mimetic cMET receptor agonist in IND‑enabling development for fibrotic disorders. The company is led by CEO Tim Knotnerus and recently raised $100M in Series C financing to support its clinical programs. Agomab is developing a portfolio of growth-factor-targeting antibodies and small molecule compounds that address hepatocyte growth factor (HGF) and transforming growth factor beta (TGF-ß) to repair tissues, resolve fibrotic processes and restore organ functions. Its lead candidate, AGMB-129, is a gastrointestinal-tract-restricted ALK-5 inhibitor currently in a Phase 1 trial in healthy volunteers for fibrostenotic Crohn’s disease. AGMB-447, a lung-restricted ALK-5 inhibitor for idiopathic pulmonary fibrosis, and AGMB-101, a full MET receptor agonist for organ failure, are in IND-enabling studies. The company recently added a partial MET-receptor agonist, AGMB-102, to its research pipeline. Agomab says the new capital will support clinical evaluation of its product candidates and further expand its pipeline and organization. The company is based in Ghent, Belgium. AgomAb Therapeutics develops highly specific monoclonal antibodies to modulate regenerative pathways, aiming to resolve inflammatory, metabolic, and fibrotic processes and induce structural tissue repair and functional organ recovery. Its lead candidate, AGMB-101, is an HGF-mimetic agonistic antibody targeting the MET receptor, developed using argenx’s SIMPLE Antibody™ platform, and is advancing through IND-enabling studies. The company reports preclinical studies have demonstrated AGMB-101’s potential across autoimmune, inflammatory, and fibrotic disorders. Proceeds from the Series B will fund clinical proof-of-concept studies for AGMB-101 and support expansion of the pipeline of regenerative pathway modulators. AgomAb has recently expanded its leadership team with hires for CMO, Chief Business Officer, and CFO to support clinical, corporate development, and financial activities. The company is headquartered in Ghent, Belgium. AgomAb Therapeutics develops HGF-mimetic agonistic monoclonal antibodies (“agomAbs”) intended to regenerate damaged and fibrotic tissues. Founded in 2017 and based in Ghent, Belgium, the company has generated a comprehensive preclinical package showing applications in fibrotic, inflammatory, autoimmune and degenerative diseases. Its platform aims to combine the regenerative and anti-fibrotic biology of HGF with the favorable drug-like properties of antibodies. AgomAb exercised an exclusive license with argenx for SIMPLE Antibodies™ developed under argenx’s Innovative Access Program. The company has assembled an experienced leadership team including CEO Tim Knotnerus, founder and CSO Paolo Michieli, and CDO Torsten Dreier. AgomAb is backed by an international syndicate of life-sciences venture investors and is positioned to advance its preclinical programs toward clinical development.

Total raised

$332M

Funding rounds

5

Latest round

Series D

Latest activity

Oct 2024